TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Optimal Levels of Dietary Dairy on Modulation of Adolescent Weight
Brief Summary: SPECIFIC AIM The aim of this study is to determine if increasing calcium intake to recommended levels with dairy foods in adolescent females with habitually low calcium intake and above-the-median body mass index (BMI) for sex and age will decrease body fat gain compared to similar females who continue their low calcium intake. .

HYPOTHESIS Post-menarcheal adolescent girls with habitually low calcium intake who consume dairy foods providing at least 1200 mg of calcium per day will have a smaller increase in percent body fat, as measured by dual energy absorptiometry, during one year than post-menarcheal adolescent girls on a usual diet of 600 mg of calcium per day or less.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Experimental | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Experimental; Assigned to Arm(s): 1
B: Arm Label: high calcium diet; Type: EXPERIMENTAL; Interventions: Behavioral: counseling on increasing calcium intake | Arm Label: normal calcium diet; Type: ACTIVE_COMPARATOR; Interventions: Other: observation | Intervention Type: BEHAVIORAL; Name: counseling on increasing calcium intake; Assigned to Arm(s): high calcium diet | Intervention Type: OTHER; Name: observation; Assigned to Arm(s): normal calcium diet
C: Arm Label: Intervention arm; Type: EXPERIMENTAL; Interventions: Behavioral: Improve access to the school breakfast program | Arm Label: Comparison arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Improve access to the school breakfast program; Assigned to Arm(s): Intervention arm
D: Arm Label: HEALTH[e]TEEN; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: HEALTH[e]TEEN | Arm Label: HEALTH[e]TEEN + CST; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: HEALTH[e]TEEN + CST | Intervention Type: BEHAVIORAL; Name: HEALTH[e]TEEN; Assigned to Arm(s): HEALTH[e]TEEN | Intervention Type: BEHAVIORAL; Name: HEALTH[e]TEEN + CST; Assigned to Arm(s): HEALTH[e]TEEN + CST

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Peer Debriefing Versus Instructor Debriefing for Interprofessional Simulation Based Education (PICS
Brief Summary: Crisis management is important for operating room practice and non-technical skills are acknowledged as key to ensure patient safety in these situations. Unfortunately, it can be difficult to find instructors with appropriate experience. A peer-led team debriefing is led by the team it self rather than an external expert instructor but remains a reflective process. Incorporating peer-led debriefing compared to expert-led debriefing may increase access to an interprofessional crisis resource management course using simulation.

The goals of the study are to observe the effect of an interprofessional peer-led team debriefing in the change in performance of non-technical skills of team performance and to compare it with the "gold standard" of expert-led debriefing on the performance of non-technical skills during a simulated operating room crisis.

The investigators hypothesize that interprofessional peer-led debriefing will improve the performance of non-technical skills of the team during simulated intraoperative crisis management and that this improvement will be equivalent to the "gold standard" expert-led debriefing.


Options:
A: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Arm Label: Virtual Ward; Type: EXPERIMENTAL; Interventions: Other: Virtual Ward | Intervention Type: OTHER; Name: Virtual Ward; Assigned to Arm(s): Virtual Ward | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Usual Care
B: Arm Label: Expert instructor debriefing; Type: ACTIVE_COMPARATOR; Interventions: Other: Expert instructor debriefing | Arm Label: Peer-led debriefing; Type: EXPERIMENTAL; Interventions: Other: Peer-led debriefing | Intervention Type: OTHER; Name: Peer-led debriefing; Assigned to Arm(s): Peer-led debriefing | Intervention Type: OTHER; Name: Expert instructor debriefing; Assigned to Arm(s): Expert instructor debriefing
C: Arm Label: Intervention; Type: N/A; Interventions: Behavioral: Intervention | Arm Label: Usual Care; Type: N/A; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): Intervention
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Information feedback | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Information feedback | Intervention Type: BEHAVIORAL; Name: Information feedback; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Information feedback; Assigned to Arm(s): Arm 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Brief Summary: The study is designed to assess the efficacy of Glatiramer Acetate (GA) injection 40 mg administered three times a week compared to placebo in subjects with RRMS, as measured by the number of confirmed relapses during the 12 month placebo controlled period. The study has two periods:

* Placebo Controlled Period: 12 months of 40 mg administered three times a week by subcutaneous injection or matching placebo.
* Open Label Extension Period: All subjects will continue treatment with GA 40 mg administered three times a week, until this dose strength is commercially available for the treatment of relapsing remitting multiple sclerosis (RRMS) patients or until the development of this GA dose regimen is stopped by the Sponsor


Options:
A: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab | Arm Label: Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Natalizumab; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2
B: Arm Label: Fingolimod 1.25 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod 1.25 mg | Arm Label: Fingolimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod 0.5 mg | Arm Label: Interferon β-1a 30 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon β-1a 30 µg | Intervention Type: DRUG; Name: Fingolimod 1.25 mg; Assigned to Arm(s): Fingolimod 1.25 mg | Intervention Type: DRUG; Name: Fingolimod 0.5 mg; Assigned to Arm(s): Fingolimod 0.5 mg | Intervention Type: DRUG; Name: Interferon β-1a 30 µg; Assigned to Arm(s): Interferon β-1a 30 µg
C: Arm Label: GA 40 mg / GA 40 mg; Type: EXPERIMENTAL; Interventions: Drug: Glatiramer acetate (GA) | Arm Label: Placebo / GA 40 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Glatiramer acetate (GA), Drug: Placebo | Intervention Type: DRUG; Name: Glatiramer acetate (GA); Assigned to Arm(s): GA 40 mg / GA 40 mg, Placebo / GA 40 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo / GA 40 mg
D: Arm Label: BAF312 10 mg/2 mg; Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 2 mg/2 mg; Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 1.25 mg/2 mg; Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 .5 mg/2 mg; Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 .25 mg/2 mg; Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Intervention Type: DRUG; Name: BAF312; Assigned to Arm(s): BAF312 .25 mg/2 mg, BAF312 .5 mg/2 mg, BAF312 1.25 mg/2 mg, BAF312 10 mg/2 mg, BAF312 2 mg/2 mg

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Remote Ischaemic Preconditioning for Heart Surgery
Brief Summary: The purpose of this study is to evaluate the effects of Remote Ischaemic Preconditioning on perioperative ischaemic injury in patients undergoing cardiac surgery compared to control intervention.


Options:
A: Arm Label: BIS Monitor guided algorithm; Type: EXPERIMENTAL; Interventions: Device: BIS Monitor guided algorithm | Arm Label: Volatile anesthetic guided algorithm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Volatile anesthetic guided algorithm | Intervention Type: DEVICE; Name: BIS Monitor guided algorithm; Assigned to Arm(s): BIS Monitor guided algorithm | Intervention Type: BEHAVIORAL; Name: Volatile anesthetic guided algorithm; Assigned to Arm(s): Volatile anesthetic guided algorithm
B: Arm Label: RIPC; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Remote Ischemic Preconditioning | Arm Label: CONTROL; Type: SHAM_COMPARATOR; Interventions: Procedure: Control/sham procedure (blood pressure cuff) | Intervention Type: PROCEDURE; Name: Remote Ischemic Preconditioning; Assigned to Arm(s): RIPC | Intervention Type: PROCEDURE; Name: Control/sham procedure (blood pressure cuff); Assigned to Arm(s): CONTROL
C: Intervention Type: PROCEDURE; Name: Orthogeriatric intervention; Assigned to Arm(s): N/A
D: Arm Label: Deeper sedation; Type: ACTIVE_COMPARATOR; Interventions: Device: Deeper sedation | Arm Label: Moderate sedation; Type: ACTIVE_COMPARATOR; Interventions: Device: Moderate sedation | Intervention Type: DEVICE; Name: Deeper sedation; Assigned to Arm(s): Deeper sedation | Intervention Type: DEVICE; Name: Moderate sedation; Assigned to Arm(s): Moderate sedation

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Remote Ischaemic Preconditioning for Heart Surgery
Brief Summary: The purpose of this study is to evaluate the effects of Remote Ischaemic Preconditioning on perioperative ischaemic injury in patients undergoing cardiac surgery compared to control intervention.


Options:
A: Arm Label: Remote preconditioning; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Remote ischemic preconditioning | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Placebo | Intervention Type: PROCEDURE; Name: Remote ischemic preconditioning; Assigned to Arm(s): Remote preconditioning | Intervention Type: PROCEDURE; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: RIPC; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Remote Ischemic Preconditioning | Arm Label: CONTROL; Type: SHAM_COMPARATOR; Interventions: Procedure: Control/sham procedure (blood pressure cuff) | Intervention Type: PROCEDURE; Name: Remote Ischemic Preconditioning; Assigned to Arm(s): RIPC | Intervention Type: PROCEDURE; Name: Control/sham procedure (blood pressure cuff); Assigned to Arm(s): CONTROL
C: Arm Label: Preconditioning; Type: EXPERIMENTAL; Interventions: Procedure: Remote ischemic conditioning | Arm Label: Postconditioning; Type: EXPERIMENTAL; Interventions: Procedure: Remote ischemic conditioning | Arm Label: Pre and postconditioning; Type: EXPERIMENTAL; Interventions: Procedure: Remote ischemic conditioning | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Procedure: Sham | Intervention Type: PROCEDURE; Name: Remote ischemic conditioning; Assigned to Arm(s): Postconditioning, Pre and postconditioning, Preconditioning | Intervention Type: PROCEDURE; Name: Sham; Assigned to Arm(s): Control
D: Arm Label: Flavanol rich cocoa; Type: EXPERIMENTAL; Interventions: Other: Cocoa | Arm Label: flavanol poor cocoa drink; Type: EXPERIMENTAL; Interventions: Other: Cocoa | Intervention Type: OTHER; Name: Cocoa; Assigned to Arm(s): Flavanol rich cocoa, flavanol poor cocoa drink

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Remote Ischaemic Preconditioning for Heart Surgery
Brief Summary: The purpose of this study is to evaluate the effects of Remote Ischaemic Preconditioning on perioperative ischaemic injury in patients undergoing cardiac surgery compared to control intervention.


Options:
A: Arm Label: remote ischemic preconditioning; Type: EXPERIMENTAL; Interventions: Other: remote ischemic preconditioning (RIPC) | Intervention Type: OTHER; Name: remote ischemic preconditioning (RIPC); Assigned to Arm(s): remote ischemic preconditioning
B: Arm Label: Thrombolysis + Remote perconditioning; Type: EXPERIMENTAL; Interventions: Procedure: Thrombolysis + remote perconditioning | Arm Label: Thrombolysis; Type: ACTIVE_COMPARATOR; Interventions: Drug: Actilyse | Intervention Type: DRUG; Name: Actilyse; Assigned to Arm(s): Thrombolysis | Intervention Type: PROCEDURE; Name: Thrombolysis + remote perconditioning; Assigned to Arm(s): Thrombolysis + Remote perconditioning
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Remote ischemic preconditioning (RIPC) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: SHAM | Intervention Type: PROCEDURE; Name: Remote ischemic preconditioning (RIPC); Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: SHAM; Assigned to Arm(s): 2
D: Arm Label: RIPC; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Remote Ischemic Preconditioning | Arm Label: CONTROL; Type: SHAM_COMPARATOR; Interventions: Procedure: Control/sham procedure (blood pressure cuff) | Intervention Type: PROCEDURE; Name: Remote Ischemic Preconditioning; Assigned to Arm(s): RIPC | Intervention Type: PROCEDURE; Name: Control/sham procedure (blood pressure cuff); Assigned to Arm(s): CONTROL

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Low Glycemic Load Diets in Latino Children at Risk for Type 2 Diabetes
Brief Summary: The purpose of this study are to:

1. compare two diet plans - a low-glycemic load (low-GL) diet and a low-fat diet. A low-GL diet is expected to keep blood sugar levels more normal, and because the sugar levels stay normal, prevent rapid rises of insulin in the blood. We want to test if Hispanic children at-risk for type 2 diabetes who are given a low-GL diet will have less insulin resistance, will lose more weight, and will decrease their chance of getting type 2 diabetes.
2. compare the effects of Low-GL and high-GL meals on appetitive, hormonal, and metabolic responses of obese Hispanic youth under controlled, standardized conditions. We want to test if children fed low-GL meals would have lower glucose and lower insulin responses, report less hunger and consume less energy than those fed high-GL meals.


Options:
A: Arm Label: A: Study diet; Type: PLACEBO_COMPARATOR; Interventions: Drug: metformin and rosiglitazone | Arm Label: B: Study diet plus Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin and rosiglitazone | Arm Label: C: Study diet plus metformin and avandia; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin and rosiglitazone | Intervention Type: DRUG; Name: metformin and rosiglitazone; Assigned to Arm(s): A: Study diet, B: Study diet plus Metformin, C: Study diet plus metformin and avandia
B: Intervention Type: DIETARY_SUPPLEMENT; Name: Low carbohydrate; Assigned to Arm(s): N/A
C: Arm Label: Low glycemic load dietary plan; Type: EXPERIMENTAL; Interventions: Behavioral: Low Glycemic Load Diet versus Low Fat Diet | Arm Label: Low fat diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low Glycemic Load Diet versus Low Fat Diet | Intervention Type: BEHAVIORAL; Name: Low Glycemic Load Diet versus Low Fat Diet; Assigned to Arm(s): Low fat diet, Low glycemic load dietary plan
D: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Other: Weight loss intervention | Arm Label: Control Group (delayed intervention); Type: EXPERIMENTAL; Interventions: Other: Weight loss intervention | Intervention Type: OTHER; Name: Weight loss intervention; Assigned to Arm(s): Control Group (delayed intervention), Intervention Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Primary Care Treatment for Overweight Adolescent Females
Brief Summary: This project will examine the effectiveness of a primary care based intervention to help overweight teen girls adopt healthy lifestyle practices. Participants are adolescent females at select Kaiser Permanente Northwest primary care clinics with a body mass index above the 90th percentile. Teens will be randomly assigned to (1) a behavioral weight control program (enriched intervention), (or 2) usual-care (control). Primary care providers of teens in the intervention condition are given customized plans describing the teen's eating and physical activity habits and instructions on how to best work with these teens and their families. The behavioral weight control program is specifically tailored for teen girls and includes separate group meetings for teens and parents, follow-up telephone contacts with their group leader, and coordinated feedback from the teen's primary care provider.


Options:
A: Intervention Type: BEHAVIORAL; Name: Low glycemic index diet; Assigned to Arm(s): N/A
B: Arm Label: Healthy lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Healthy lifestyle managment | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Healthy lifestyle managment; Assigned to Arm(s): Healthy lifestyle intervention
C: Arm Label: Mandometer; Type: EXPERIMENTAL; Interventions: Device: Mandometer, Behavioral: Lifestyle | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Device: Mandometer | Intervention Type: DEVICE; Name: Mandometer; Assigned to Arm(s): Control, Mandometer | Intervention Type: BEHAVIORAL; Name: Lifestyle; Assigned to Arm(s): Mandometer
D: Arm Label: Mot. & Fam. Weight Loss + Online Interv.; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational and Family Weight Loss, Behavioral: Online Intervention | Arm Label: Mot. & Fam. Weight Loss + Online Control; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational and Family Weight Loss, Behavioral: Online Control | Arm Label: Basic Health Educ. & Online Interv.; Type: EXPERIMENTAL; Interventions: Behavioral: Basic Health Education, Behavioral: Online Intervention | Arm Label: Basic Health Educ. & Online Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Basic Health Education, Behavioral: Online Control | Intervention Type: BEHAVIORAL; Name: Motivational and Family Weight Loss; Assigned to Arm(s): Mot. & Fam. Weight Loss + Online Control, Mot. & Fam. Weight Loss + Online Interv. | Intervention Type: BEHAVIORAL; Name: Basic Health Education; Assigned to Arm(s): Basic Health Educ. & Online Control, Basic Health Educ. & Online Interv. | Intervention Type: BEHAVIORAL; Name: Online Intervention; Assigned to Arm(s): Basic Health Educ. & Online Interv., Mot. & Fam. Weight Loss + Online Interv. | Intervention Type: BEHAVIORAL; Name: Online Control; Assigned to Arm(s): Basic Health Educ. & Online Control, Mot. & Fam. Weight Loss + Online Control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Forearm Exercise on Flow Mediated Vasodilation Prior to Arteriovenous Fistula Placement for Hemodialysis
Brief Summary: The study hypothesis is that 6 weeks of repetitive handgrip exercise will improve endothelial function and venous compliance in pre-dialysis patients with an estimated glomerular filtration rate of less than or equal to 20 ml/min. If proven correct then arm exercise might be useful to improve the success rate for a surgically created arteriovenous fistula in the forearm to become usable as a vascular access for hemodialysis.


Options:
A: Arm Label: The handgrip exercise; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: The handgrip exercise | Arm Label: The dumbbell exercise; Type: EXPERIMENTAL; Interventions: Behavioral: The dumbbell exercise | Intervention Type: BEHAVIORAL; Name: The handgrip exercise; Assigned to Arm(s): The handgrip exercise | Intervention Type: BEHAVIORAL; Name: The dumbbell exercise; Assigned to Arm(s): The dumbbell exercise
B: Arm Label: Repetitive handgrip exercise; Type: EXPERIMENTAL; Interventions: Other: Repetitive arm exercise | Arm Label: No arm exercise; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Repetitive arm exercise; Assigned to Arm(s): Repetitive handgrip exercise
C: Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Other: experimental group | Arm Label: Group control; Type: SHAM_COMPARATOR; Interventions: Other: experimental group | Intervention Type: OTHER; Name: experimental group; Assigned to Arm(s): Experimental group, Group control
D: Arm Label: Preoperative isometric exercise (PIE) group; Type: EXPERIMENTAL; Interventions: Device: Isometric exercises using Hand grip and elastic bands | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Isometric exercises using Hand grip and elastic bands; Assigned to Arm(s): Preoperative isometric exercise (PIE) group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-label Phase IIb Trial of Maintenance Therapy With a MUC1 Dendritic Cell Vaccine (Cvac™) for Epithelial Ovarian Cancer Patients in First or Second Remission
Brief Summary: The purpose of this study is to determine the safety and efficacy of an investigational therapeutic agent (Cvac) in ovarian cancer patients in first or second remission and to determine its ability to prevent cancer from returning.

Study objectives

Primary objectives:

* To confirm the safety of administering Cvac in this population.
* To determine the effects of Cvac on progression-free survival (PFS).

Secondary objectives:

* To determine overall survival (OS) for ovarian cancer patients who receive Cvac after achieving remission in the first or second-line setting.
* Evaluation of host immunologic response to Cvac administration.


Options:
A: Arm Label: Abagovomab; Type: EXPERIMENTAL; Interventions: Biological: Abagovomab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Abagovomab; Assigned to Arm(s): Abagovomab | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: BIOLOGICAL; Name: CDX-1401 in combination with Resiquimod and/or Poly-ICLC; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: CDX-1401; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: Resiquimod; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: poly-ICLC; Assigned to Arm(s): N/A
C: Arm Label: 1 Catumaxomab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Catumaxomab (Removab), Procedure: paracentesis | Arm Label: 2:; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Catumaxomab (Removab); Assigned to Arm(s): 1 Catumaxomab | Intervention Type: PROCEDURE; Name: paracentesis; Assigned to Arm(s): 1 Catumaxomab
D: Arm Label: Non-randomized Cvac; Type: EXPERIMENTAL; Interventions: Biological: Cvac | Arm Label: Randomized Cvac; Type: EXPERIMENTAL; Interventions: Biological: Cvac | Arm Label: Observational standard of care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Cvac; Assigned to Arm(s): Non-randomized Cvac, Randomized Cvac

Answer: D